CN113559251A - Soluble micro-needle patch and preparation method and application thereof - Google Patents

Soluble micro-needle patch and preparation method and application thereof Download PDF

Info

Publication number
CN113559251A
CN113559251A CN202110687960.XA CN202110687960A CN113559251A CN 113559251 A CN113559251 A CN 113559251A CN 202110687960 A CN202110687960 A CN 202110687960A CN 113559251 A CN113559251 A CN 113559251A
Authority
CN
China
Prior art keywords
solution
microneedle
microneedle patch
needle body
molecular polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202110687960.XA
Other languages
Chinese (zh)
Other versions
CN113559251B (en
Inventor
王丽珍
宁天勤
姚艳
樊瑜波
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beihang University
Original Assignee
Beihang University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beihang University filed Critical Beihang University
Priority to CN202110687960.XA priority Critical patent/CN113559251B/en
Publication of CN113559251A publication Critical patent/CN113559251A/en
Application granted granted Critical
Publication of CN113559251B publication Critical patent/CN113559251B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0241—Containing particulates characterized by their shape and/or structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0046—Solid microneedles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0053—Methods for producing microneedles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Birds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention provides a soluble microneedle patch, a preparation method and application thereof. The microneedle patch comprises a main body support component and sustained-release microspheres, wherein the main body support component consists of a needle body and a base layer. The neurotoxin sustained-release microspheres are prepared from functional components and a biocompatible high polymer material and are coated in the needle body; the needle body is prepared from a hydrophilic high molecular polymer and magnesium particles; the base layer is prepared from antibacterial high polymer materials. The functional component is botulinum toxin A. The microneedle patch disclosed by the invention effectively penetrates the stratum corneum barrier of the skin, and as the hydrophilic high polymer material is quickly dissolved in the skin, the slow-release microspheres containing the effective components are implanted into the dermis layer for long-term effective component slow release, so that long-term treatment of diseases is realized.

Description

Soluble micro-needle patch and preparation method and application thereof
Technical Field
The invention belongs to the technical field of noninvasive soluble microneedles, and particularly relates to a soluble microneedle patch and a preparation method and application thereof.
Background
Botulinum toxin is useful in the treatment of a variety of diseases, including hyperhidrosis. Hyperhidrosis generally manifests as a condition of excessive secretion of sweat from the sweat glands. Statistically, 1% to 3% of the world's population suffers from hyperhidrosis. Patients with hyperhidrosis often encounter the following situations in life: drench clothing in formal social situations; the odor is bad due to a lot of sweating in professional occasions, or the embarrassment is caused by the odor brought by over-sweating in armpits when people contact with people at a short distance. According to a sampling survey of 2017 in the united states, about one third of hyperhidrosis patients indicate that spontaneous sweating is almost unbearable and often plagues common daily activities.
The currently common treatment modalities for hyperhidrosis are aluminium antiperspirants and iontophoresis. Aluminum antiperspirants, however, have been tested extensively to demonstrate little antiperspirant effect, but rather to mask body odor by virtue of the perfume ingredients incorporated into the antiperspirant. The iontophoresis method requires a complicated apparatus and a long treatment time, which causes great inconvenience to patients. With the development of therapeutic techniques, in recent years, botulinum toxin a (also referred to as botulinum toxin type a) has come to be widely used for the treatment of hyperhidrosis, and by injecting botulinum toxin a, neurotransmitters between sympathetic nerves and sweat glands are greatly reduced, thereby reducing sweat secretion from sweat glands, with a good antiperspirant effect.
Although botulinum A injection simplifies the procedure compared to iontophoresis, it still requires regular procedures by professional medical personnel. In order to further improve the convenience of handling, the prior art also proposes transdermal administration of botulinum toxin a to an area to be treated using an injection-type hollow microneedle, but on the one hand, it is difficult to achieve both the convenience of handling and the high efficiency of administration. On the other hand, botulinum toxin A, a neurotoxin protein, has a retention property of itself which limits the amount of botulinum toxin A administered per injection, and a therapeutic effect can be obtained in a short period of time, but it is difficult to satisfy the long-term treatment of hyperhidrosis.
In addition to the treatment of hyperhidrosis, botulinum toxin is also commonly used in the cosmetic and plastic industries, and botulinum toxin a is used to treat hypertrophy of the massaged muscles, remove wrinkles, and the like. However, when used in these therapeutic fields, they also have problems of poor convenience, low administration efficiency to the human body, and poor long-lasting therapeutic effect. Under the background, the technical problem to be solved in the field is how to search a convenient, efficient and safe soluble microneedle treatment device for long-acting treatment.
Disclosure of Invention
The invention solves the technical problems that a microneedle device in the prior art is difficult to have both convenience and high efficiency of operation and is not suitable for long-acting treatment, further provides a soluble microneedle patch which is convenient, efficient and safe and can be used for long-acting treatment, and also provides a preparation method and application of the soluble microneedle patch.
The technical scheme adopted by the application for solving the technical problems is as follows:
a dissolvable microneedle patch comprising: the main body supporting part comprises a base layer and needle bodies distributed on the base layer; the needle body is prepared from a hydrophilic high molecular polymer, and the hydrophilic high molecular polymer is at least one of monomer polymers or copolymers of polyvinylpyrrolidone and derivatives thereof, trehalose, dextran, carboxymethyl cellulose, chondroitin sulfate, polyvinyl alcohol, silk fibroin and hyaluronic acid; the needle body is distributed with slow release microspheres and magnesium particles; the sustained-release microspheres are prepared from functional components and a biocompatible high-molecular polymer material; the biocompatible high molecular polymer material is at least one of polyvinyl alcohol, polyethylene glycol, polylactic acid, dextran, methylcellulose, carboxymethylcellulose, polyethylene glycol, hypromellose, hydroxymethyl cellulose, hydroxypropyl methylcellulose and gelatin; the functional component is botulinum toxin A.
The molecular weight range of the botulinum toxin A is 150-900 kDa.
The diameter of the magnesium particles is 10-100 mu m.
The base layer is made of antibacterial high polymer materials.
The antibacterial high polymer material is chitosan.
The loading capacity of the botulinum toxin A of each microneedle patch is 220-260U.
The microneedle body is conical and 300-800 mu m in height.
The preparation method of the soluble microneedle patch comprises the following steps of (1) blending the functional components with a microsphere solution, adding the functional components into a water phase to rotate at a high speed, and forming precipitates in the water phase by the slow release microspheres consisting of the biocompatible high polymer material and the functional components; the microsphere solution is a mixed solution prepared from the biocompatible high-molecular polymer material and a solvent, and the concentration of the biocompatible high-molecular polymer material in the mixed solution is 50-400 g/L; the solvent is at least one selected from dioxane, benzene, toluene, pentane, hexane, methanol, ethanol, diethyl ether, ethyl acetate, acetone and carbon tetrachloride; (2) separating the slow release microsphere precipitate, uniformly mixing with magnesium particles, and placing into the groove part of the needle body of the microneedle female die; adding the needle body solution into a needle body groove of the microneedle concave die, firstly carrying out low-speed centrifugation or vacuum drying treatment under the low-temperature condition, then scraping the redundant needle body solution, and then continuously carrying out centrifugation or vacuum drying treatment under the room-temperature condition; the needle body solution is an aqueous solution prepared from the hydrophilic high-molecular polymer and water, and the concentration of the hydrophilic high-molecular polymer in the aqueous solution is 20-200 g/L; (3) adding the base solution into a microneedle female die, carrying out vacuum treatment in a vacuum drier at low temperature, scraping off redundant needle point solution, and drying at 30-40 ℃ for 4-6 hours; (4) and (3) placing the microneedle concave die at normal temperature for drying, and taking out the solidified material in the microneedle concave die to obtain the soluble microneedle patch.
The soluble microneedle patch is used for treating hyperhidrosis or removing wrinkles.
The basic solution is prepared by dissolving bacteriostatic high-molecular polymer materials in acetic acid aqueous solution and performing dialysis and rotary evaporation.
The soluble microneedle patch has the advantages that:
the invention relates to a microneedle or microneedle patch, which is characterized in that a microneedle body is made of hydrophilic high molecular polymer and magnesium particles, a base layer is made of antibacterial high molecular polymer material, a biocompatible high molecular polymer material and slow-release microspheres loaded with functional components and made of botulinum toxin A are used for preparing a soluble microneedle for long-acting treatment, and after the soluble microneedle acts on the skin, the dissolution of the soluble high molecular polymer is accelerated along with the reaction of magnesium and body fluid, so that a needle point is quickly and efficiently separated from the microneedle base layer, and the slow-release microspheres loaded with the functional components are quickly implanted into the skin, so that the microneedle body can efficiently act on a human body, and the administration efficiency is improved. Meanwhile, the slow release microspheres loaded with the botulinum toxin A are implanted into a dermis layer, and the biocompatible high polymer material can be slowly degraded under the skin to release the loaded bioactive components; therefore, the sustained release of the botulinum toxin A can be carried out for a long time, and the botulinum toxin A is irreversibly attached to the presynaptic nerve terminal to inhibit the acetylcholine secretion of the nerve junction part and the sweat secretion of sweat gland, thereby realizing the long-term treatment of the hyperhidrosis.
The dissolvable microneedle patch of the present invention has a variety of uses, including wrinkle removal applications in addition to use in treating hyperhidrosis.
In order to make the technical scheme of the soluble microneedle patch, the preparation method and the application thereof more clear and clear, the invention is further explained with reference to the accompanying drawings and the specific embodiments.
Drawings
Fig. 1 is a structure of a dissolvable microneedle patch according to the present invention;
wherein the reference numerals are:
1-a needle body; 2-magnesium particles; 3-sustained release microspheres; 4-base layer.
Detailed Description
The present embodiment provides a dissolvable microneedle patch, which has a structure as shown in fig. 1, and includes a main body supporting portion, the main body supporting portion further includes a base layer and needles distributed on the base layer; the needle body is distributed with slow release microspheres and magnesium particles.
The micro-needle concave die is used in the preparation process of the soluble micro-needle patch in the embodiment and comprises a rectangular sheet-shaped groove body, a plurality of needle body grooves are formed in the bottom surface of the sheet-shaped groove body, and the needle body grooves are conical and are matched with the needle bodies in shape. The height of the needle body groove is 300-800 mu m and is matched with the height of the needle body. In this embodiment, the distribution density of the needle grooves in the microneedle cavity is 20 × 20/cm2. In the present embodiment, the area of each piece is 1cm2The loading amount of the botulinum toxin A of the microneedle patch is 220-260U.
This embodiment further provides methods for preparing various dissolvable microneedle patches by the following examples.
Example 1
The method for preparing the dissolvable microneedle patch described in this embodiment includes the following steps:
(1) blending the functional component botulinum toxin A with the microsphere solution, adding the functional component botulinum toxin A into the water phase, and stirring at a high speed of 450 r/min; wherein the water phase adopts deionized water; the microsphere solution is a mixed solution prepared from polyvinyl alcohol and a solvent, the concentration of the polyvinyl alcohol in the mixed solution is 50g/L, and the solvent is dioxane; after stirring, the slow release microspheres consisting of the polyvinyl alcohol and the functional components form precipitates in the water phase. The molecular weight range of the botulinum toxin A in the embodiment is 150-900 kDa.
(2) Separating the slow release microsphere precipitate generated in the step (1) in a filtering or centrifugal separation mode, uniformly mixing the slow release microsphere and magnesium particles, and placing the mixture into the groove part of the needle body of the microneedle female die; then adding the needle body solution into a needle body groove of the microneedle concave die, and performing vacuum drying treatment at the low temperature of 20 ℃ for 2 hours; and then scraping off the redundant needle body solution, and continuing to perform vacuum drying treatment at room temperature until the needle body is dried.
The diameter of the magnesium particles used in the step is 10-100 mu m, and the mass ratio of the added magnesium particles to the slow-release microspheres is 1: 1.
In this embodiment, the solution of the needle body is an aqueous solution prepared from polyvinylpyrrolidone and water, and the concentration of the polyvinylpyrrolidone in the aqueous solution is 20 g/L.
(3) Adding the base solution into a microneedle concave die, carrying out vacuum drying treatment in a vacuum dryer at low temperature of 21 ℃, scraping redundant needle point solution, and drying for 4-6 hours at 37 ℃;
in this embodiment, the basic solution is prepared by dissolving chitosan, which is an antibacterial high molecular polymer material, in an acetic acid aqueous solution, and then dialyzing and rotary evaporating the solution. The preparation method comprises the following steps: dissolving chitosan in acetic acid water solution with the concentration of 1% V/V to prepare primary chitosan solution with the concentration of 20g/L, and dialyzing the primary chitosan solution at room temperature for 48 hours in ultrapure water to remove excessive acetic acid; after the ultrapure water dialysis is completed, the pH value of the primary chitosan solution is adjusted to 6, and then the primary chitosan solution with the concentration of 100g/L is obtained through rotary evaporation.
(4) And (3) placing the microneedle concave die at normal temperature for drying, and taking out the cured material in the microneedle concave die to obtain the soluble microneedle patch for long-acting treatment of hyperhidrosis.
Example 2
The method for preparing the dissolvable microneedle patch described in this embodiment includes the following steps: (1) mixing the functional component botulinum toxin A with the microsphere solution, then adding the mixture into the water phase, and stirring at a high speed of 850 r/min; wherein the water phase adopts ultrapure water; the microsphere solution is a mixed solution prepared from polyethylene glycol and a solvent, the concentration of the polyethylene glycol in the mixed solution is 100g/L, and the solvent is a toluene solvent; after stirring, the slow release microspheres consisting of the polyethylene glycol and the functional components form precipitates in the water phase. The molecular weight range of the botulinum toxin A in the embodiment is 150-900 kDa.
(2) Separating the slow release microsphere precipitate generated in the step (1) in a filtering or centrifugal separation mode, uniformly mixing the slow release microsphere and magnesium particles, and placing the mixture into the groove part of the needle body of the microneedle female die; then adding the needle body solution into a needle body groove of the microneedle concave die, and firstly carrying out low-speed centrifugal treatment at the low temperature of 5 ℃ for 6 hours; and then scraping off the redundant needle body solution, and continuing to perform low-speed centrifugation treatment at room temperature until the needle body is dry. The rotation speed when the low-speed centrifugation treatment is carried out is 4000 r/min.
The diameter of the magnesium particles used in the step is 10-100 mu m, and the mass ratio of the added magnesium particles to the slow-release microspheres is 2: 3.
In the embodiment, the needle body solution is an aqueous solution prepared from trehalose and water, and the concentration of the trehalose in the aqueous solution is 200 g/L.
(3) Adding the base solution into a microneedle concave die, carrying out vacuum drying treatment in a vacuum dryer at low temperature of 21 ℃, scraping redundant needle point solution, and drying for 4-6 hours at 37 ℃;
in this embodiment, the basic solution is prepared by dissolving chitosan, which is an antibacterial high molecular polymer material, in an acetic acid aqueous solution, and then dialyzing and rotary evaporating the solution. The specific preparation method is the same as that of example 1.
(4) And (3) placing the microneedle concave die at normal temperature for drying, and taking out the cured material in the microneedle concave die to obtain the soluble microneedle patch for long-acting treatment of hyperhidrosis.
Example 3
The method for preparing the dissolvable microneedle patch described in this embodiment includes the following steps:
(1) blending the functional component botulinum toxin A with the microsphere solution, then adding the mixture into the water phase, and stirring at a high speed of 550 r/min; wherein the water phase adopts deionized water; the microsphere solution is a mixed solution prepared from polylactic acid and a solvent, the concentration of the polylactic acid in the mixed solution is 400g/L, and the solvent is methanol; after stirring, the slow release microspheres consisting of the polylactic acid and the functional components form precipitates in a water phase. The molecular weight range of the botulinum toxin A in the embodiment is 150-900 kDa.
(2) Separating the slow release microsphere precipitate generated in the step (1) in a filtering or centrifugal separation mode, uniformly mixing the slow release microsphere and magnesium particles, and placing the mixture into the groove part of the needle body of the microneedle female die; then adding the needle body solution into a needle body groove of the microneedle concave die, and performing vacuum drying treatment at 21 ℃ for 3 hours; and then scraping off the redundant needle body solution, and continuing to perform vacuum drying treatment at room temperature until the needle body is dried.
The diameter of the magnesium particles used in the step is 10-100 mu m, and the mass ratio of the added magnesium particles to the slow-release microspheres is 1: 3.
In this embodiment, the needle body solution is an aqueous solution prepared from hyaluronic acid and water, and the concentration of hyaluronic acid in the aqueous solution is 100 g/L.
(3) Adding the base solution into a microneedle concave die, carrying out vacuum drying treatment in a vacuum dryer at the low temperature of 20 ℃, scraping redundant needle point solution, and drying at 37 ℃ for 4-6 hours;
in this embodiment, the basic solution is prepared by dissolving chitosan, which is an antibacterial high molecular polymer material, in an acetic acid aqueous solution, and then dialyzing and rotary evaporating the solution. The preparation method comprises the following steps: dissolving chitosan in acetic acid water solution with the concentration of 1% V/V to prepare primary chitosan solution with the concentration of 20g/L, and dialyzing the primary chitosan solution at room temperature for 48 hours in ultrapure water to remove excessive acetic acid; after the ultrapure water dialysis is completed, the pH value of the primary chitosan solution is adjusted to 6, and then the primary chitosan solution with the concentration of 100g/L is obtained through rotary evaporation.
(4) And (3) placing the microneedle concave die at normal temperature for drying, and taking out the cured material in the microneedle concave die to obtain the soluble microneedle patch for long-acting treatment of hyperhidrosis.
In the soluble microneedle patch prepared in examples 1 to 3 of this embodiment, when in use, the needle tip side of the patch is tightly attached to the skin, and after the needle body acts on the skin, the dissolution of the soluble high molecular polymer can be accelerated along with the reaction of magnesium and body fluid, so that the needle tip and the microneedle base layer are separated quickly and efficiently, the sustained release microspheres loaded with botulinum toxin a are implanted into the dermis layer, so that the sustained release of botulinum toxin a can be carried out for a long time, the corrosion inhibition time can be as long as 12 months, and the sustained release effect is very excellent. Botulinum toxin A inhibits sympathetic nerve activity and neurotransmitters between sympathetic nerves and sweat glands are greatly reduced, thereby enabling long-term treatment of hyperhidrosis. In addition to being used to treat hyperhidrosis, the dissolvable microneedle patch of this embodiment may also be used to remove wrinkles.
In the soluble microneedle patch of examples 1 to 3 in this embodiment, in addition to the polyvinylpyrrolidone, trehalose, and hyaluronic acid in the above examples, the hydrophilic polymer in the needle body may be at least one of a copolymer of polyvinylpyrrolidone, a monomer polymer or copolymer of a polyvinylpyrrolidone derivative, dextran, carboxymethyl cellulose, chondroitin sulfate, polyvinyl alcohol, and silk fibroin. The biocompatible high molecular polymer material in the slow release microspheres can also be selected from at least one of dextran, methylcellulose, carboxymethylcellulose, polyethylene glycol, hypromellose, hydroxymethyl cellulose, hydroxypropyl methylcellulose and gelatin.
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the present invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present invention should be subject to the claims.

Claims (9)

1. A dissolvable microneedle patch, comprising:
the main body supporting part comprises a base layer and needle bodies distributed on the base layer;
the needle body is prepared from a hydrophilic high molecular polymer, and the hydrophilic high molecular polymer is at least one of monomer polymers or copolymers of polyvinylpyrrolidone and derivatives thereof, trehalose, dextran, carboxymethyl cellulose, chondroitin sulfate, polyvinyl alcohol, silk fibroin and hyaluronic acid;
the needle body is distributed with slow release microspheres and magnesium particles; the sustained-release microspheres are prepared from functional components and a biocompatible high-molecular polymer material; the biocompatible high molecular polymer material is at least one of polyvinyl alcohol, polyethylene glycol, polylactic acid, dextran, methylcellulose, carboxymethylcellulose, polyethylene glycol, hypromellose, hydroxymethyl cellulose, hydroxypropyl methylcellulose and gelatin; the functional component is botulinum toxin A.
2. The soluble microneedle patch according to claim 1, wherein said botulinum toxin a has a molecular weight in the range of 150-900 kDa.
3. The dissolvable microneedle patch according to claim 1, wherein said magnesium particles are 10-100 μ ι η in diameter.
4. The dissolvable microneedle patch according to claim 1, wherein the base layer is made of bacteriostatic high molecular polymer material.
5. The dissolvable microneedle patch according to claim 4, wherein the bacteriostatic polymeric material is chitosan.
6. The dissolvable microneedle patch according to any one of claims 1-5, wherein each microneedle patch has a botulinum loading of 220- > 260U.
7. The dissolvable microneedle patch according to any one of claims 1-6, wherein said microneedle body is tapered having a height of 300-800 μm.
8. The method of preparing a dissolvable microneedle patch according to claim 1, comprising the steps of:
(1) blending the functional components with a microsphere solution, adding the mixture into a water phase, and rotating at a high speed, wherein the slow release microspheres composed of the biocompatible high polymer material and the functional components form precipitates in the water phase; the microsphere solution is a mixed solution prepared from the biocompatible high-molecular polymer material and a solvent, and the concentration of the biocompatible high-molecular polymer material in the mixed solution is 50-400 g/L; the solvent is at least one selected from dioxane, benzene, toluene, pentane, hexane, methanol, ethanol, diethyl ether, ethyl acetate, acetone and carbon tetrachloride;
(2) separating the slow release microsphere precipitate, uniformly mixing with magnesium particles, and placing into the groove part of the needle body of the microneedle female die; adding the needle body solution into a needle body groove of the microneedle concave die, firstly carrying out low-speed centrifugation or vacuum drying treatment under the low-temperature condition, then scraping the redundant needle body solution, and then continuously carrying out centrifugation or vacuum drying treatment under the room-temperature condition; wherein the needle body solution is an aqueous solution prepared from the hydrophilic high molecular polymer and water, and the concentration of the hydrophilic high molecular polymer in the aqueous solution is 20-200 g/L;
(3) adding the base solution into a microneedle female die, carrying out vacuum treatment in a vacuum drier at low temperature, scraping off redundant needle point solution, and drying at 30-40 ℃ for 4-6 hours;
(4) and (3) placing the microneedle concave die at normal temperature for drying, and taking out the solidified material in the microneedle concave die to obtain the soluble microneedle patch.
9. Use of the dissolvable microneedle patch of claims 1-7 for treating hyperhidrosis or removing wrinkles.
CN202110687960.XA 2021-06-21 2021-06-21 Soluble microneedle patch and preparation method and application thereof Active CN113559251B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110687960.XA CN113559251B (en) 2021-06-21 2021-06-21 Soluble microneedle patch and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110687960.XA CN113559251B (en) 2021-06-21 2021-06-21 Soluble microneedle patch and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN113559251A true CN113559251A (en) 2021-10-29
CN113559251B CN113559251B (en) 2024-06-25

Family

ID=78162395

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110687960.XA Active CN113559251B (en) 2021-06-21 2021-06-21 Soluble microneedle patch and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN113559251B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113908425A (en) * 2021-10-31 2022-01-11 江苏熙美生物科技有限公司 Method for rapidly preparing microneedle patch
CN114099936A (en) * 2021-10-31 2022-03-01 江苏熙美生物科技有限公司 Long-acting soluble microneedle for cosmetic filling and sustained-release administration and preparation method thereof
KR20230107137A (en) * 2022-01-07 2023-07-14 주식회사 대웅테라퓨틱스 Stable composition comprising botulinum toxin and microstructure comprising thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106422045A (en) * 2016-09-05 2017-02-22 中国科学院理化技术研究所 Flexible slow-release micro-needle patch and preparation method thereof
CN109646673A (en) * 2017-10-12 2019-04-19 秀杰股份公司 The micro-structure preparation technique of botulin toxin
CN110870846A (en) * 2018-08-31 2020-03-10 中科微针（北京）科技有限公司 Rapidly implantable sustained-release microneedle patch and preparation method thereof
CN110870943A (en) * 2018-08-31 2020-03-10 中科微针（北京）科技有限公司 Implantable two-section type microneedle patch and preparation method thereof
CN112703030A (en) * 2018-08-15 2021-04-23 阿勒根公司 Microneedle array with active ingredients

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106422045A (en) * 2016-09-05 2017-02-22 中国科学院理化技术研究所 Flexible slow-release micro-needle patch and preparation method thereof
CN109646673A (en) * 2017-10-12 2019-04-19 秀杰股份公司 The micro-structure preparation technique of botulin toxin
CN112703030A (en) * 2018-08-15 2021-04-23 阿勒根公司 Microneedle array with active ingredients
CN110870846A (en) * 2018-08-31 2020-03-10 中科微针（北京）科技有限公司 Rapidly implantable sustained-release microneedle patch and preparation method thereof
CN110870943A (en) * 2018-08-31 2020-03-10 中科微针（北京）科技有限公司 Implantable two-section type microneedle patch and preparation method thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
刘卫等: "《经皮给药纳米技术》", vol. 1, 中国医药科技出版社, pages: 310 *
巫传玲;: "微针技术在经皮和其他组织器官给药领域的研究进展", 中国医药工业杂志, vol. 1, no. 09, 27 September 2018 (2018-09-27), pages 310 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113908425A (en) * 2021-10-31 2022-01-11 江苏熙美生物科技有限公司 Method for rapidly preparing microneedle patch
CN114099936A (en) * 2021-10-31 2022-03-01 江苏熙美生物科技有限公司 Long-acting soluble microneedle for cosmetic filling and sustained-release administration and preparation method thereof
KR20230107137A (en) * 2022-01-07 2023-07-14 주식회사 대웅테라퓨틱스 Stable composition comprising botulinum toxin and microstructure comprising thereof
KR102614567B1 (en) * 2022-01-07 2023-12-19 주식회사 대웅테라퓨틱스 Stable composition comprising botulinum toxin and microstructure comprising thereof

Also Published As

Publication number Publication date
CN113559251B (en) 2024-06-25

Similar Documents

Publication Publication Date Title
CN113559251B (en) Soluble microneedle patch and preparation method and application thereof
CN113491675B (en) Microneedle wound plaster for preventing scars and preparation method thereof
CN109528695B (en) Microneedle transdermal drug delivery patch for treating rheumatoid arthritis and preparation method thereof
US20150141910A1 (en) Microneedles for therapeutic agent delivery with improved mechanical properties
KR20100038071A (en) Process for preparing solid microstructures by blowing and solid microstructures prepared by the same
JP2008179629A (en) Cosmetic sheet
CN110237054B (en) Scar repairing material and preparation method thereof
TW201938175A (en) Hyaluronic acid microstructure having excellent dissolving properties
CN104826228A (en) Biological paster for skin regeneration and maintenance
CN112999297A (en) Microneedle patch for scar treatment and preparation method thereof
CN111558128A (en) Soluble microneedle array carrying scar repairing medicine and preparation method
KR20150128481A (en) Composition for application of skin comprising of extracellular matrix and thermo sensitive macromolecule
CN114099635A (en) Soluble hair-growing microneedle and preparation method thereof
CN112826847A (en) Microneedle patch for removing acne and removing acne marks and preparation method thereof
CN104921961A (en) Degradable biological microneedle sticker with multi-effect restoration
WO2018026400A1 (en) Agaroid compositions and methods of use thereof
CN104840428B (en) A kind of hyaluronic acid-chitosan microballoon for being loaded with epidermal growth factor and its preparation method and application
CN103405478A (en) Periplaneta americana extract microgel and preparation method thereof
CN112386503A (en) Microneedle mask containing active peptides and preparation method thereof
KR20210121576A (en) Polymeric micro particles, a method of preparing polymeric micro particles, medical composition, cosmetic composition, medical articles and cosmetic articles using the same
CN115737532A (en) Supermolecule salicylic acid composite microneedle patch, and preparation method and application thereof
KR20200142844A (en) A topical pharmaceutical composition for treating or preventing scar
TWI767886B (en) Soluble microneedle for protein or peptide and preparing method thereof
CN114479205A (en) Temperature-sensitive hydrogel for treating wounds and preparation method thereof
CN114010583A (en) Hydrogel for treating diabetic foot and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant